| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/SREP28511 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1038/srep28511 |
| P932 | PMC publication ID | 4919791 |
| P698 | PubMed publication ID | 27338805 |
| P50 | author | Samir K Maji | Q57321626 |
| Subhadeep Das | Q87175547 | ||
| P2093 | author name string | Pradeep K Singh | |
| Narendra Nath Jha | |||
| Reeba S Jacob | |||
| Dhiman Ghosh | |||
| Irishi N N Namboothiri | |||
| Arunagiri Anoop | |||
| Narasimham Ayyagari | |||
| P2860 | cites work | Relationships between the sequence of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity | Q24293089 |
| Inhibition and disaggregation of α-synuclein oligomers by natural polyphenolic compounds | Q24298231 | ||
| Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models | Q24315670 | ||
| The thioflavin T fluorescence assay for amyloid fibril detection can be biased by the presence of exogenous compounds | Q24316146 | ||
| Structure-activity relationships of amyloid beta-aggregation inhibitors based on curcumin: influence of linker length and flexibility. | Q50681726 | ||
| Inhibition of alpha-synuclein fibril assembly by small molecules: analysis using epitope-specific antibodies. | Q54409967 | ||
| Genetics of Parkinson's disease and biochemical studies of implicated gene products: Commentary | Q57364174 | ||
| Effects of curcumin on cytochrome P450 and glutathione S-transferase activities in rat liver | Q70818052 | ||
| Occurrence of orally administered curcuminoid as glucuronide and glucuronide/sulfate conjugates in rat plasma | Q73268752 | ||
| The newly discovered Parkinson's disease associated Finnish mutation (A53E) attenuates α-synuclein aggregation and membrane binding | Q85652193 | ||
| A new microcellular cytotoxicity test based on calcein AM release | Q36761954 | ||
| Neuroprotective effects of curcumin | Q36849490 | ||
| Infrared spectroscopy of proteins | Q36907942 | ||
| Curcumin analogs with altered potencies against HIV-1 integrase as probes for biochemical mechanisms of drug action | Q38342984 | ||
| Structure based aggregation studies reveal the presence of helix-rich intermediate during α-Synuclein aggregation | Q38898283 | ||
| Curcumin modulates α-synuclein aggregation and toxicity. | Q39178579 | ||
| The non-core regions of human lysozyme amyloid fibrils influence cytotoxicity | Q39681329 | ||
| A causative link between the structure of aberrant protein oligomers and their toxicity. | Q39750915 | ||
| Curcumin binds to the pre-fibrillar aggregates of Cu/Zn superoxide dismutase (SOD1) and alters its amyloidogenic pathway resulting in reduced cytotoxicity. | Q41457084 | ||
| Hydrogen peroxide mediates amyloid beta protein toxicity | Q41460857 | ||
| BRICHOS domains efficiently delay fibrillation of amyloid β-peptide. | Q41856638 | ||
| ANS binding reveals common features of cytotoxic amyloid species | Q43021800 | ||
| Phenolic and enolic hydroxyl groups in curcumin: which plays the major role in scavenging radicals? | Q43279717 | ||
| Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure | Q43735123 | ||
| The Parkinson's disease-associated H50Q mutation accelerates α-Synuclein aggregation in vitro | Q43977429 | ||
| Inhibition of amyloid fibril growth and dissolution of amyloid fibrils by curcumin-gold nanoparticles. | Q44171513 | ||
| Conformational behavior and aggregation of alpha-synuclein in organic solvents: modeling the effects of membranes | Q44339521 | ||
| Direct observation of amyloid fibril growth monitored by thioflavin T fluorescence | Q44368597 | ||
| Synthesis of Glycosylcurcuminoids | Q44644120 | ||
| The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils | Q44851129 | ||
| Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Abeta oligomerization | Q45034193 | ||
| Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? | Q45300712 | ||
| Evidence for a partially folded intermediate in alpha-synuclein fibril formation | Q46097239 | ||
| Anti-oxidant activities of curcumin and related enones | Q46465133 | ||
| Ferulic acid destabilizes preformed beta-amyloid fibrils in vitro | Q46695279 | ||
| Evidence of fibril-like β-sheet structures in a neurotoxic amyloid intermediate of Alzheimer's β-amyloid. | Q46866171 | ||
| Complexation of amyloid fibrils with charged conjugated polymers | Q46912921 | ||
| Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease | Q48353748 | ||
| Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays | Q25939005 | ||
| Bioavailability of curcumin: problems and promises | Q28257125 | ||
| Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism | Q28298521 | ||
| Curcumin promotes A-beta fibrillation and reduces neurotoxicity in transgenic Drosophila | Q28480606 | ||
| A chemical analog of curcumin as an improved inhibitor of amyloid Abeta oligomerization | Q28481562 | ||
| Neuroprotective effects of curcumin on 6-hydroxydopamine-induced Parkinsonism in rats: behavioral, neurochemical and immunohistochemical studies | Q28572559 | ||
| Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo | Q29619108 | ||
| Targeting insulin amyloid assembly by small aromatic molecules: toward rational design of aggregation inhibitors | Q30992370 | ||
| Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production | Q32061424 | ||
| A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders | Q33203491 | ||
| FT-IR approaches on amyloid fibril structure | Q33221237 | ||
| High-performance liquid chromatography analysis of curcumin in rat plasma: application to pharmacokinetics of polymeric micellar formulation of curcumin | Q33277064 | ||
| Curcumin inhibits aggregation of alpha-synuclein | Q33314363 | ||
| Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo | Q33500696 | ||
| The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation | Q33606422 | ||
| Molecular basis for preventing α-synuclein aggregation by a molecular tweezer. | Q33675844 | ||
| The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. | Q33955271 | ||
| Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. | Q34111667 | ||
| Alpha-synuclein and Parkinson's disease | Q34160107 | ||
| Effects of Various Flavonoids on the α-Synuclein Fibrillation Process | Q34211735 | ||
| Therapeutic approaches to protein-misfolding diseases | Q34285075 | ||
| The biochemistry of Parkinson's disease | Q34426026 | ||
| Curcumin inhibits FtsZ assembly: an attractive mechanism for its antibacterial activity | Q34584082 | ||
| In vivo demonstration that alpha-synuclein oligomers are toxic | Q34652122 | ||
| Curcumin as "Curecumin": from kitchen to clinic. | Q34694680 | ||
| Stability of curcumin in buffer solutions and characterization of its degradation products. | Q34742746 | ||
| Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy | Q34964783 | ||
| Safety and pharmacological characterization of the molecular tweezer CLR01 - a broad-spectrum inhibitor of amyloid proteins' toxicity | Q35148785 | ||
| Familial Parkinson disease-associated mutations alter the site-specific microenvironment and dynamics of α-synuclein | Q35199433 | ||
| Design strategies for anti-amyloid agents. | Q35209288 | ||
| Inhibition of amyloid fibril formation and cytotoxicity by a chemical analog of Curcumin as a stable inhibitor | Q35619865 | ||
| Curcumin prevents aggregation in α-synuclein by increasing reconfiguration rate. | Q35841861 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | curcumin | Q312266 |
| Synuclein | Q24767155 | ||
| P304 | page(s) | 28511 | |
| P577 | publication date | 2016-06-24 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | Effect of curcumin analogs onα-synuclein aggregation and cytotoxicity | |
| P478 | volume | 6 |
| Q90497044 | Advances in the development of imaging probes and aggregation inhibitors for alpha-synuclein |
| Q93096530 | Cell-Based Screen Using Amyloid Mimic β23 Expression Identifies Peucedanocoumarin III as a Novel Inhibitor of α-Synuclein and Huntingtin Aggregates |
| Q38733078 | Natural product-based amyloid inhibitors. |
| Q64075638 | Plant Extracts and Phytochemicals Targeting -Synuclein Aggregation in Parkinson's Disease Models |
| Q37622863 | Repurposing doxycycline for synucleinopathies: remodelling of α-synuclein oligomers towards non-toxic parallel beta-sheet structured species. |
Search more.